Fiche publication
Date publication
septembre 2026
Journal
Transplantation and cellular therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Pr RUBIO Marie Thérèse
,
Pr PAGLIUCA Simona
Tous les auteurs :
Gagelmann N, Salit RB, Schroeder T, Chiusolo P, Finazzi MC, Gurnari C, Pagliuca S, Rautenberg C, Rubio MT, Maciejewski JP, Vannucchi A, Guglielmelli P, Nozzoli C, Leimkühler N, Angelucci E, Gambella M, Rambaldi A, Reinhardt HC, Bacigalupo A, Scott BL, Heidel FH, Popat U, Kröger N
Lien Pubmed
Résumé
Allogeneic hematopoietic cell transplantation is the only curative treatment for myelofibrosis, but failure occurs by two mechanistically distinct routes: relapse of the neoplasm, which reflects its underlying genetics, and non-relapse mortality, which reflects whether the patient and graft tolerate the procedure. Established prognostic systems either lack molecular granularity or were derived in the non-transplant setting, and all collapse these two routes into a single survival estimate. None can indicate why an individual patient is at risk, or which class of intervention might reduce that risk.
Mots clés
mortality, myelofibrosis, relapse, risk score, transplantation
Référence
Transplant Cell Ther. 2026 09 17;:
